Chronic rhinosinusitis (CRS) is among the most prevalent chronic medical conditions globally. A survey of Canadian households reported the prevalence of CRS to be 5%. CRS is a clinical syndrome defined by persistent symptomatic inflammation of the mucosa in the nasal cavities and sinuses. A common subtype of CRS is CRS with nasal polyps (CRSwNP), which is identified through endoscopy or imaging
Can benign vascular anomalies transform into highly malignant angiosarcoma (AS), and is a more aggressive biopsy/surgical approach warranted in certain cases of these anomalies?
Preoperatively administered GCS improved olfaction in CRS patients with nasal polyps is comparable to surgery, and changes in steroids predicted olfactory outcome postoperatively.
Statin use is associated with decreased rates of chronic rhinosinusitis (CRS) based on a nationally representative sample of outpatient visits in the United States.
Eosinophil-derived SEMA4D aggravates ECRS, and serum SEMA4D levels reflect disease severity.
There is insufficient evidence to support the use of acupuncture in CRS.
LDMs provided favorable outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Multiple therapeutic options may be effective for treating mild pediatric OSA including observation, management with anti-inflammatory medications, and surgery.
Olfaction can be improved by sinus surgery in about every second chronic rhinosinusitis (CRS) patient.
The use of topical high-volume budesonide irrigation does not appear to have a significant effect on IOP and carries a low risk of HPA axis suppression when used long term.